- recruitingPHASE3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
This study is testing a new medicine, glofitamab, for people in the UK with a type of blood cancer called mantle cell lymphoma. It aims to see if glofitamab works better than standard treatments for those whose cancer has returned or isn't responding to past therapies.
United States · Australia · Brazil - recruitingPHASE1, PHASE2
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
This study is testing a new drug, NUC-7738, for people with advanced cancers like solid tumours and lymphoma. It aims to see how safe the drug is, how it works in the body, and if it helps treat these cancers, sometimes combined with pembrolizumab.
United Kingdom - recruiting
Assessing the Presence of CT-DNA in Lymphoma Associated HLH
This study looks at a new way to diagnose lymphoma earlier in adults with a serious condition called HLH. By checking for cancer DNA in blood samples, researchers hope to improve treatment and survival for people who develop HLH because of lymphoma.
United Kingdom - active not recruitingPHASE3
PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma
This study looks at whether a special scan (PET scan) after chemotherapy can help doctors decide if people with early-stage Hodgkin lymphoma need more treatment, like radiotherapy. It aims to see if some patients can safely avoid extra treatment.
United Kingdom - recruitingPHASE1, PHASE2
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
This study is looking at a medicine called ponatinib for children aged 1 to 17 with certain types of cancer, like leukemia and lymphoma. We want to see how safe it is and how well it works when other treatments haven't helped or aren't suitable.
Belgium · France · Italy - active not recruitingPHASE1
First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228
This study is testing a new discovery medicine called BYON4228, along with an existing medicine called Rituximab. It's for people with a type of blood cancer called lymphoma that hasn't responded well to previous treatments. It aims to see if the new medicine is safe and how well it works.
Italy · Netherlands · Spain - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This study is testing a drug called alectinib for different types of cancer that have a special gene change called ALK. It's already used for some lung cancers, and now doctors want to see if it can help other cancers with the same change.
United Kingdom - recruitingPHASE1, PHASE2
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
This study looks at a new drug, AZD3470, alone or with other cancer medicines, for people with blood cancers like lymphoma. It aims to see if it's safe, how it works, and if it helps shrink the cancer. This is an early-stage trial.
United States · Australia · China - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A safety study of PF-08046044/SGN-35C in adults with advanced cancers
This study is looking at a new medicine called PF-08046044/SGN-35C for adults with certain advanced cancers, including types of lymphoma. It's an early-stage study to see if the medicine is safe and how it works in people for the first time.
France · Spain · Denmark - recruitingPHASE3
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
This study is looking at a new medicine called duvelisib for people in the UK with a specific type of T-cell lymphoma that has come back or not responded to previous treatments. It compares duvelisib to standard treatments like gemcitabine or bendamustine to see if it helps patients live longer without their cancer getting worse.
Belgium · Czechia · Denmark - active not recruitingPHASE1, PHASE2
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
This study looks at a new drug, ASTX660, for people with advanced cancers like solid tumours and lymphomas. It checks how safe the drug is, the best dose to use, and if it helps shrink tumours, especially when standard treatments aren't working.
United States · Belgium · Canada - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients with Relapsed or Refractory Lymphoma
This early-stage study is looking at a new medicine called HMPL-523 for people with lymphoma that has come back or not responded to other treatments. The main goals are to check if it's safe, how well the body handles it, and if it shows any signs of working.
Poland - recruitingPHASE1, PHASE2
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
This study looks at a new drug, repotrectinib, for children and young adults (up to 25) with certain advanced cancers. It checks if the drug is safe and helps shrink tumours that have specific genetic changes called ALK, ROS1, or NTRK.
United States · Australia · Canada - recruitingPHASE1, PHASE2
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
This study looks at a medicine called pembrolizumab for children aged 6 months to 17 years with certain advanced cancers that haven't responded to other treatments. It's an immunotherapy that helps the body's immune system fight cancer, and researchers want to see if it can shrink these cancers.
United States · Brazil · France